The antagomir treatment group also increased the expression of some of the cytotoxicity genes in T cells, such as PRF1, indicating that miR-651-5p may activate the tumor-killing function; however, the effect may be weak, as the tumor volume in the group was not significantly decreased compared with the control group. The gene discussed is PRF1; the disease is neoplasm.